{
  "id": "resp_096fd615e3c7def000693c96c3e05481949a83b56142f507b3",
  "object": "response",
  "created_at": 1765578435,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_096fd615e3c7def000693c96c428648194acbfdb047cf76b99",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_096fd615e3c7def000693c96d1003c8194bf2fe6412f93f3c2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Small molecule inhibitors\" CDK12 triple-negative breast cancer"
      }
    },
    {
      "id": "rs_096fd615e3c7def000693c96d3889c81949a6835cf91d60f86",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_096fd615e3c7def000693c96e550f08194be40cb08ce394573",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12 inhibitor phase 1 trial"
      }
    },
    {
      "id": "rs_096fd615e3c7def000693c96e6bcd48194b74604f77a3907f8",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_096fd615e3c7def000693c96ed26bc8194aeabac1262d9eeb5",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"Small molecule inhibitors\" drug name"
      }
    },
    {
      "id": "rs_096fd615e3c7def000693c96eea0088194b558a4031a2b06e5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_096fd615e3c7def000693c970067888194bc3e2d935d671524",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "{\n  \"validated\": false,\n  \"assets\": [],\n  \"rejected_reason\": \"Candidate identifier \\\"Small molecule inhibitors\\\" is a non-specific modality/class label (not a unique drug asset). Sponsor, target, indication, development stage, and geography cannot be unambiguously attributed to a single asset.\"\n}"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "xhigh",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 19810,
    "input_tokens_details": {
      "cached_tokens": 4736
    },
    "output_tokens": 4954,
    "output_tokens_details": {
      "reasoning_tokens": 4885
    },
    "total_tokens": 24764
  },
  "user": null,
  "metadata": {}
}